Substances with a short half-life (HWL) (subcutaneous)
Exenatide (Byetta®) 2006 EU authorization (type 2 DM)
Liraglutide (Victosa®) 2009 EU authorization (type 2 DM)
Liraglutide (Victosa®) 2019 EU authorization (type 2 DM (children from 10 yrs.)
Liraglutide (Saxenda®) 2015 EU approval (weight reduction)
Liraglutide (Saxenda®) 2021 EU approval (weight reduction children from 12 years)
Lixisenatide (Lyxumia®) 2013 EU approval (type 2 DM)
Substances with long half-life (subcutaneous)
Exenatide (Bydureon®) 2011 EU approval (type 2 DM)
Dulaglutide (Trulicity®) 2014 EU approval (type 2 DM)
Semaglutide s.c. (Ozempic®) EU approval 2018 (type 2 DM);
Semaglutide s.c. (Wegovy®) 2022 Wegovy® (for weight loss).
Semaglutide s.c. (Wegovy®) EU approval 2024 (weight reduction for children aged 12 and over)
Tirzepatide (Mounjaro®) combination preparation with GIP (Gastric Inhibitory Polypeptide) EU approval 2022 (type 2 DM; extension of approval for weight management 2023)
Semaglutide oral (Rybelsus®) EU approval 2020, not yet on the market (as of Dec. 2024)